← Browse by Condition
Medical Condition

pancreatic ductal adenocarcinoma

Total Trials
10
Recruiting Now
10
Trial Phases
EARLY_Phase 1, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for pancreatic ductal adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic ductal adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for pancreatic ductal adenocarcinoma?
ClinicalMetric currently tracks 10 actively recruiting clinical trials for pancreatic ductal adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic ductal adenocarcinoma?
pancreatic ductal adenocarcinoma research spans Phase 1 (5 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic ductal adenocarcinoma clinical trial?
Eligibility criteria for pancreatic ductal adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
5
Phase 2
4
Top Sponsors
Dana-Farber Cancer Institute 1 trial
Changhai Hospital 1 trial
Lipidica, a.s. 1 trial
City of Hope Medical Center 1 trial
Seagen, a wholly owned subsidiary of Pfizer 1 trial

Recruiting Clinical Trials

NCT06122896 EARLY_Phase 1
Recruiting
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Enrollment
5,000 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT04146298 Phase 1, Phase 2
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Enrollment
30 pts
Location
China
Sponsor
Changhai Hospital
View Trial →
NCT06549725
Recruiting
Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening
Enrollment
419 pts
Location
Czechia
Sponsor
Lipidica, a.s.
View Trial →
NCT06388967
Recruiting
Pancreatic Cancer Detection Consortium
Enrollment
2,000 pts
Location
United States, Japan...
Sponsor
City of Hope Medical Center
View Trial →
NCT06131840 Phase 1
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Enrollment
914 pts
Location
United States, Canad...
Sponsor
Seagen, a wholly owned subsidi...
View Trial →
NCT04291651
Recruiting
UCSF PANC Cyst Registry
Enrollment
4,000 pts
Location
United States
Sponsor
University of California, San ...
View Trial →
NCT06330441
Recruiting
Pancreatic Cancer Screening in a Population at High Risk
Enrollment
700 pts
Location
Czechia
Sponsor
Masaryk Memorial Cancer Instit...
View Trial →
NCT07199764 Phase 2
Recruiting
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
Enrollment
100 pts
Location
United States
Sponsor
University of Pennsylvania
View Trial →
NCT06598007 Phase 1, Phase 2
Recruiting
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Enrollment
78 pts
Location
United States
Sponsor
Crossignal Therapeutics, Inc.
View Trial →
NCT05431270 Phase 1, Phase 2
Recruiting
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Enrollment
40 pts
Location
United States
Sponsor
Phanes Therapeutics
View Trial →

Related Conditions

pancreatic cancer (4) pancreatic neoplasms (3) hereditary diseases (2) pancreatitis chronic (2) pdac (1) pdac pancreatic ductal adenocarcinoma (1) pancreatic neoplasm (1) advanced cancer (1) pancreas cancer (1) pancreatic carcinoma (1) pancreatic adenocarcinoma (1) pancreatic cancer stage i (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology